Nevirapine-induced hepatotoxicity and pharmacogenetics: A retrospective study in a population from Mozambique
Academic Article
Publication Date:
2010
abstract:
Aims: Nevirapine is widely used to treat HIV-1 infection to prevent mother-to-child transmission; unfortunately adverse drug reactions have been reported. Our aim was to identify genes/variants involved in nevirapine-induced hepatotoxicity. Materials & methods: Patients from Mozambique, 78 with nevirapine-induced hepatotoxicity and 78 without adverse events, were genotyped for ABCB1, CYP2B6, CYP3A4 and CYP3A5 gene variants. We conducted a case-control association study and a genotype/phenotype correlation analysis. Results: The ABCB1 c.3435C>T SNP was associated with hepatotoxicity (p = 0.038), with the variant T allele showing a protective effect (odds ratio: 0.42). Moreover, four SNPs in the CYP2B6 and CYP3A5 genes resulted significantly correlated with transaminase values. In particular, for the CYP2B6 c.983T>C SNP, the difference in the alanine aminotransferase mean values were highly significant between TT and TC genotypes (p < 0.001). Conclusion: Our preliminary results confirm the contribution of the ABCB1 c.3435C>T SNP in nevirapine-induced hepatotoxicity risk and, at the same time, suggest the necessity for further studies. © 2010 Future Medicine Ltd.
Iris type:
1.1 Articolo in rivista
Keywords:
ABCB1; Adverse reactions; CYP2B6; CYP3A4; CYP3A5; Hepatotoxicity; Nevirapine; NVP; Pharmacogenetics; Pharmacogenomics; SNP
List of contributors:
Ciccacci, C.; Borgiani, P.; Ceffa, S.; Sirianni, E.; Marazzi, M. C.; Doro Altan, A. M.; Paturzo, G.; Bramanti, P.; Novelli, G.; Palombi, L.
Published in: